gene therapies
Digital/ Market Access/ R&D/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?
mike.smith@pharmaphorum.com
2019, biosimilars, Brexit, China, digital, gene therapies, M&A, NIne for 2019, pricing, Sarah Rickwood
0 Comment
X
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?
https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
Market Access/ R&D/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis
Nine for 2019: Opportunities for pharma
mike.hammerton@pharmaphorum.com
2019, biosimilars, China, gene therapies, industry, Multichannel, NIne for 2019, real world data, RWE
0 Comment
X
Nine for 2019: Opportunities for pharma
https://pharmaphorum.com/views-and-analysis/nine-for-2019-opportunities-for-pharma/